Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Assessment of Gastro-Intestinal Function to a Mixed Meal by Non-invasive Imaging

8 aprile 2014 aggiornato da: Nottingham University Hospitals NHS Trust

Pilot Study: Assessment of Gastric Motor and Sensory Function to a Mixed Liquid and Solid Test Meal by Gamma Scintigraphy, Magnetic Resonance Imaging and a Nutrient Drink Test in Health and Patients With Disorders of Gastric Function

Dyspeptic symptoms, such as pain after eating, bloating and nausea all have major impact on quality of life and health care costs. When no structural cause is identified, patients are diagnosed with functional dyspepsia. This trial aims to identify objective abnormalities of stomach function that explain patient's symptoms and establish diagnosis. Another group are diabetic patients who can often develop similar symptoms, labelled as diabetic gastroparesis. In some cases this is associated with delayed gastric emptying but not all.

24 patients with functional dyspepsia will be studied and 24 healthy controls (to establish normal ranges) and 24 diabetic patients with symptoms of functional dyspepsia.

The utility of 3 different non-invasive investigations will be assessed. At screening the nutrient drink test (NDT) asks the patient to drink 40ml of milkshake (0.75kcal/ml) every minute and score symptoms every 5 minutes. The patient continues until they reach the maximum tolerated volume.

Participants will then be randomized to undergo non-invasive imaging on two separate test days by magnetic resonance imaging (MRI) and gastric scintigraphy MRI will be completed with the patient ingesting 400ml of milkshake (identical to NDT) and 12 agar beads (no additional calories) of known breaking strength. The emptying of the stomach will be visualised with the MRI alongside symptom recording.

Gamma scintigraphy will ingest the same meal as for the MRI scan but radioactive labelling will allow the rate of liquid and solid meal emptying to be visualised alongside symptom recording.

Additionally, blood sugars will be recorded before nutrient drink test and at 15 and 30 minutes following ingestion of 400ml of milkshake and 12 agar beads.

Data will be analyzed to assess the association of objective abnormalities of gastric function and patient symptoms. Additionally the results of non-invasive imaging by MRI and GS will be compared to assess the optimal measurement of gastric function and emptying in this clinical scenario.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Anticipato)

72

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Nottingham, Regno Unito, NG7 2YH
        • National Institute of Health Research Biomedical Research Unit, Nottingham Digestve Diseases Centre, University of Nottingham,

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Be an adult patient above 18 years old
  2. Have a body mass index of >18 and <30kg.m2 and not exceed a waist circumference of 99cm at 5cm above ileal crest
  3. Be able to give voluntary informed consent and from whom written consent to participate has been obtained.
  4. Be able to understand the study, willing to co-operate with the study procedures and able to attend all study assessments.
  5. Be willing to abstain from alcohol for 24 hours before and during the imaging appointment.
  6. Be willing to fast from midnight prior to the screening and imaging appointment
  7. Be able to ingest at least 400ml nutrient liquid (0.75kcal/ml at 40ml/min) during a Nutrient Drinking Test without experiencing more than moderate dyspeptic symptoms (no such restriction for patients with dyspeptic symptoms)
  8. Be able to swallow a solid agar bead between 7.5 and 11.5 mm in diameter
  9. Be willing to consent to their General Practitioner (GP) being informed of their participation.

Exclusion Criteria:

  1. Have a history of gastrointestinal disease or surgery (other than appendicitis or hysterectomy)
  2. Have ongoing disease requiring active management (including impaired renal clearance GFR <50 mL/min/1.73 m2)
  3. Have a documented history of alcohol or drug abuse
  4. Fail to satisfy the investigator's assessment of fitness to participate based on a survey of inclusion and exclusion criteria
  5. Have consumed alcohol within 24 hours of start of study
  6. Have participated in a similar study involving the use of radioisotopes in the previous 3 months such that participating in the current study would exceed the recommended yearly exposure limit (5mSv)
  7. Take any medication which may affect oesophageal or gastric motility for a minimum 7 days
  8. Have had previous history of gastric surgery
  9. Have active upper gastrointestinal diseases
  10. Have an active Eating Disorder
  11. Have an allergy to milk protein (milk based, lactose free test meal)
  12. Be a vegan
  13. Be pregnant or breastfeeding
  14. Have any contraindication to MRI scanning according to local guidelines

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum volume ingested at nutrient drink test (ml)
Lasso di tempo: Study Day
Maximum of milkshake ingested at maximum satiety
Study Day
Gastric emptying rate (ml/min) for liquids
Lasso di tempo: Study day
gastric emptying rate measured by non-invasive imaging
Study day
Gastric emptying rate (ml/min) for solids
Lasso di tempo: Study Day
Gastric emptying rate measured by non-invasive imaging
Study Day
Time taken for 50% gastric emptying (T50, minutes) for liquids
Lasso di tempo: Study day-After 50% of contents of stomach has emptied
time taken for 50% of gastric contents to leave the stomach
Study day-After 50% of contents of stomach has emptied
Time take for 50% gastric emptying (T50, minutes) solids
Lasso di tempo: Study day-after 50% of contents of stomach has emptied
Time taken for 50% of gastric contents to leave the stomach
Study day-after 50% of contents of stomach has emptied

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Sensation at 200ml, 400ml and at completion of nutrient drink test (fullness, bloating, nausea, heartburn, epigastric pain)
Lasso di tempo: Study day
Visual analogue score for each sensation (score up to 100 points)
Study day
Glycaemic response at 15 minutes and 30 minutes post 400ml milkshake
Lasso di tempo: study day
Blood glucose (mmol/l)
study day
Gastric volume at 200ml nutrient ingestion
Lasso di tempo: Study day
Measurement of gastric volume (ml) on MRI and gamma scintigraphy
Study day
Gastric volume at 400ml nutrient ingestion
Lasso di tempo: study day
measurement of gastric volume (ml) on MRI and gamma scintography
study day
Gastric contractile wave contractile frequency
Lasso di tempo: study day
contractile frequency within stomach
study day
Oro-caecal Transit time
Lasso di tempo: study day
Time taken for 50% gastric contents to enter caecum
study day
Sensation threshold volume for fullness, bloating, nausea, heartburn and epigastric pain
Lasso di tempo: study day
Gastric volume recorded at time of maximum symptom scores
study day
Sensation at 200ml and 400ml ingestion of test meal (fullness, bloating, nausea, heartburn, epigastric pain)
Lasso di tempo: study day
Visual analogue score for each sensation (score up to 100 points)
study day
GI Hormone Assessment
Lasso di tempo: Study day
5 ml of blood will be taken at time 0, 30, 60 and 120 min. GI peptide hormones will then be analysed from the samples.
Study day

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Mark Fox, BMBS, MD, University of Nottingham

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 aprile 2011

Completamento primario (Effettivo)

1 aprile 2014

Completamento dello studio (Effettivo)

1 aprile 2014

Date di iscrizione allo studio

Primo inviato

10 luglio 2013

Primo inviato che soddisfa i criteri di controllo qualità

5 agosto 2013

Primo Inserito (Stima)

8 agosto 2013

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

9 aprile 2014

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 aprile 2014

Ultimo verificato

1 aprile 2014

Maggiori informazioni

Termini relativi a questo studio

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi